Siren Biotechnology is an innovative company specializing in the development of groundbreaking therapies for cancer. Established in 2021, the company is headquartered in San Francisco, California. It was founded by Nicole K. Paulk, Ph.D., an acclaimed expert in the field of AAV gene therapy. Siren Biotechnology focuses on creating universal adeno-associated virus (AAV) immuno-gene therapies that combine the strengths of AAV gene therapy and cytokine immunotherapy. As of late 2024, Siren has raised undisclosed amounts through seed funding, and its key investors include Artis Ventures and others.
May 8, 2024: Siren Biotechnology entered a partnership with Catalent for the manufacturing of AAV gene therapies. Catalent will handle process development and cGMP manufacturing of Siren's AAV vector-based therapeutic candidates, enhancing Siren's capabilities in clinical trials.
April 2024: Siren was awarded a $4 million grant from the California Institute for Regenerative Medicine (CIRM) to aid in developing novel AAV immuno-gene therapies for cancer. This funding is expected to support critical aspects of process development and bolster Siren's progress towards clinical applications.
June 2024: Siren Biotechnology was selected as the North American winner of MilliporeSigma's Advance Biotech Grant Program, which provides bioprocessing products and specialized consultation services to enhance AAV vector yield and reduce production timelines.
January 2024: The company announced a strategic partnership with WhiteLab Genomics to leverage AI for advancements in gene therapy, aimed at streamlining processes and reducing development time.
May 2023: Siren Biotechnology officially launched its Universal AAV Immuno-Gene Therapy platform at the ASGCT Annual Meeting, unveiling preclinical data that demonstrated potent anti-tumor effects in brain cancer models.
| Attribute | Information |
|---|---|
| Founding Date | 2021 |
| Headquarters | San Francisco, California, USA |
| Founders | Nicole K. Paulk, PhD |
| Revenue | Undisclosed |
| Profits | Not publicly available |
| Key Investors | Artis Ventures, Founders Fund, Lux Capital |
| Industry | Biotechnology, Cancer Therapeutics |
| Number of Employees | Not publicly available |
Siren Biotechnology was founded with the vision of combining gene therapy and immunotherapy to create a novel treatment modality for cancer. Nicole K. Paulk, Ph.D., leveraged her extensive experience in academia and the biopharmaceutical industry to establish Siren after identifying significant hurdles in existing therapies. The company quickly captured attention through its innovative approach, which utilizes AAV gene therapy to deliver immuno-modulatory cytokines directly to tumors, thus enhancing both therapeutic efficacy and safety. This method redefines the therapeutic landscape for solid tumors, targeting some of the most challenging cancers, including those of the brain and eye.
Siren Biotechnology operates within the biotechnology sector, focusing on cancer therapeutics through the use of advanced AAV vector technology. The company's flagship, Universal AAV Immuno-Gene Therapy, is designed to address critical challenges in cancer treatment.
Siren Biotechnology continues to pioneer the field with its cutting-edge therapies. The company's approach to AAV-mediated cytokine delivery offers a promising avenue for treating various oncology indications. With strategic partnerships enhancing its operational scope, Siren is well-positioned to lead in the biopharmaceutical market. It engages in continuous collaboration with key industry stakeholders to refine its processes and expand its reach, reflecting an agile model that adapts to the rapidly evolving landscape of biotechnology.
Siren Biotechnology stands as a trailblazer in cancer therapeutics, leveraging revolutionary therapeutic modalities to combat deeply ingrained challenges in oncology treatment. The combination of AAV gene therapy and cytokine immunotherapy marks a significant step forward in the development of transformative cancer treatments. As the company progresses towards clinical trials and potential commercialization, it is poised to make substantial impacts within the healthcare industry, offering new hope to patients worldwide. With a steadfast commitment to innovation and collaboration, Siren Biotechnology is set to remain influential in biotechnology advancements in the coming years.